000			04862cam a22004218i 4500
001			on1250260753
003			OCoLC
005			20240726104837.0
008			210510s2021 nyu ob 001 0 eng
010			_a2021018520
040			_aDLC _beng _erda _cDLC _dYDX _dOCLCO _dEBLCP _dUKAHL _dOCLCF _dNT
020			_a9781536196146 _q((electronic)l(electronic)ctronic)
042			_apcc
050	0	0	_aR728 _b.E266 2021
049			_aMAIN
245	1	0	_aThe economics of diseases and cures /Randall Waechter, PhD, Associate Director of Research, Assistant Dean School of Graduate Studies, and Associate Professor School of Medicine, St. George's University, West Indies, editor.
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_adata file _2rda
490	1		_aEconomic Issues, Problems and Perspectives Ser.
504			_a2
520	0		_a"This book examines the process of cure discovery and the economic impact of cures across varying diseases. It is the first time anyone has attempted to examine the [economic] returns across a wide spectrum of disease categories, using a common frame of reference"-- _cProvided by publisher.
505	0	0	_aIntro -- _tContents -- _tForeword -- _tAcknowledgments -- _tList of Acronyms -- _tSection A. Background and Measures -- _tChapter 1 -- _tThe Economics of Diseases and Cures -- _tDifferent Levels of Cures: Functional vs. Definitive -- _tMeasuring the Economic Impact of Cures: Cost Strategy vs. Cures Strategy -- _tThe Diffusion of Cures -- _tThe Value of Case Studies -- _tReferences -- _tChapter 2 -- _tTools and Assumptions -- _tData Sources -- _tTimelines -- _tDisease Categorization -- _tCure Categorization -- _tMeasures used to Assess the Value of Cures -- _tYears of Potential Life Lost (YPLL) -- _tQuality-Adjusted Life Years (QALY)
505	0	0	_aDisability-Adjusted Life Years (DALY) -- _tCure Impact -- _tCalculation Assumptions -- _tReferences -- _tSection B. Infectious Diseases -- _tChapter 3 -- _tAcquired Immunodeficiency Syndrome (AIDS/HIV) -- _tDisease Category -- _tDisease Identification, Description, and Diagnostic Criteria -- _tDisease Etiology (Cause) -- _tCurrent Prevalence/Incidence -- _tEstimated Undiagnosed and At-Risk -- _tDisease Impact -- _tYears of Potential Life Lost (YPLL) -- _tDisease Impact -- _tDisability Adjusted Life Years (DALY) -- _tHistory of the Disease and Breakthroughs -- _tCurrent Cure Status -- _tFuture Cure Obstacles
505	0	0	_aResearch Development and Treatment Costs -- _tHIV Cures: Anti-Retroviral Therapy (ART) -- _tCure Category -- _tCure Identification/Description -- _tCure History -- _tCure Science: Breakthroughs/Obstacles -- _tCure Science: Future Obstacles -- _tNumber of Patients Currently Being Treatment -- _tNumber of Patients Requiring Treatment -- _tImpact of Treatment on Years of Potential Life Lost (YPLL) -- _tImpact of Treatment on Disability-Adjusted Life Years (DALY/QALY) -- _tCost of Treatment Using ART per Patient -- _tCost of Lifetime Treatment Using ART -- _tEconomic Impact -- _tValue of Life Added -- _tHIV Cures -- _tVaccination
505	0	0	_aCure Category -- _tCure History -- _tCure Science/Cure Obstacles -- _tPhase I Trials -- _tPhase II Trials -- _tPhase III Trials -- _tReferences -- _tChapter 4 -- _tInfluenza -- _tDisease Category -- _tDisease Description, Diagnosis, and Background -- _tDisease Etiology (Cause) -- _tCurrent Prevalence/Incidence -- _tEstimated Undiagnosed/At-Risk -- _tDisease Impact -- _tYears of Potential Life Lost (YPLL) -- _tDisease Impact -- _tDisability Adjusted Life Years (DALY) -- _tHistory of the Disease and Breakthroughs -- _tCurrent Cure Status -- _tResearch, Development and Treatment Costs -- _tInfluenza Cures: Vaccinations -- _tCure Category
505	0	0	_aCure Identification/Description -- _tCure History -- _tCure Science: Breakthroughs/Obstacles -- _tCure Science/Future Cure Obstacles and Targets -- _tNumber of Patients Currently Being Treated -- _tNumber of People Requiring Treatment -- _tImpact of Treatment on Years of Potential Life Lost (YPLL) -- _tImpact of Treatment on Disability-adjusted Life Years (DALY/QALY) -- _tAverage Annual Total/Lifetime Cost of Vaccinations -- _tEconomic Impact -- _tValue of Life Added -- _tEconomic Impact -- _tValue of Reduction in DALYs/Increase in QALYs -- _tInfluenza Cures: Antivirals -- _tCure Category -- _tCure Identification/Description
530			_a2 _ub
650		0	_aMedical economics.
655		1	_aElectronic Books.
700	1		_aWaechter, Randall, _e5
856	4	0	_zClick to access digital title | log in using your CIU ID number and my.ciu.edu password. _uhttpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2913941&site=eds-live&custid=s3260518
942			_cOB _D _eEB _hR _m2021 _QOL _R _x _8NFIC _2LOC
994			_a92 _bNT
999			_c80219 _d80219
902			_a1 _bCynthia Snell _c1 _dCynthia Snell